This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

SIDNEY N. MENDELSOHN, M.D.; ARNOLD IGLAUER, M.D.

AMA Arch Intern Med. 1953;92(5):760-762.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

THE NUMBER and variety of the complications as a result of bishydroxycoumarin (Dicumarol) intoxication, or poisoning, are of staggering proportions. A review of the literature leads one to conclude that in this drug one is dealing with a truly fine pharmaceutical tool but one that without proper surveillance may easily become a lethal weapon. In the report of a fatal case of bishydroxycoumarin poisoning Duff and Shull¹ state succinctly:

The most important of all contraindications to the use of dicumarol^® is lack of reliable laboratory facilities for prothrombin determinations. Employment of this beneficial drug without laboratory control is hazardous and may result in fatal widespread hemorrhage.

Aggeler² has collected and tabulated from the American literature the number of hemorrhagic complications following bishydroxycoumarin therapy up to 1946. He reports that of a total of 1,471 patients treated with the drug hemorrhagic complications developed in 123 (8.3%). There were . . . [Full Text PDF of this Article]

Author Affiliations
CINCINNATI

From the Departments of Surgery and Internal Medicine, The Jewish Hospital.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?